 |
| Anno I | Numero 5 | Settembre 2016 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis |
| Immunotherapy is a novel treatment for advanced non-small cell lung cancer (NSCLC) patients. Immunotherapy includes two main broad classes of therapeutic vaccines and immune checkpoint inhibitors, as well as cytokines, biological response modifiers and cellular therapy. The present systematic review and meta-analysis aims to evaluate the efficacy and safety of different classes of immunotherapy in patients with advanced NSCLC. Literature search was done on Medline, Embase and Cochrane … |
| Continua a leggere |
| Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma |
| Pembrolizumab is an anti- Programmed Death 1 (PD-1) antibody approved in melanoma, non-small cell lung cancer and investigated in malignant pleural mesothelioma. The most frequent immunotherapy related autoimmune reactions include dermatitis, pneumonitis, colitis, hypophysitis, uveitis, hypothyreodism, hepatitis and interstitial nephritis. We describe a 62-year old patient diagnosed with malignant pleural mesothelioma who experienced ten days after the second dose of third line therapy with … |
| Continua a leggere |
| Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy |
| To understand the clinical impact of PD-1/L1 expression in thymoma (TM) and thymic carcinoma (TC), we evaluated the frequency of PD-1/L1 expression in pre/post chemotherapy specimens and the correlation with the treatment efficacy. The expression of PD-1/L1 was evaluated using immunohistochemistry in patients with TM or TC treated with chemotherapy between 2000 and 2014. Using formalin-fixed, paraffin-embedded tissue samples and a PD-L1 antibody, the expression of PD-L1 in the … |
| Continua a leggere |
| Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting |
| Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. In recent years, through a better understanding of the interactions between the immune system and tumor cells (TC), immunotherapy has emerged as a promising therapeutic strategy. Chemotherapy has long been reported to interfere with the immune response to the tumor and conversely, anti-tumor immunity may add to those effects. Anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, tumor … |
| Continua a leggere |
| A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing |
| Nivolumab (NIV) was recently approved in several countries for patients with pre-treated advanced non-small cell lung cancer (NSCLC). NIV is not cost-effective compared to docetaxel (DOC) for the treatment of squamous NSCLC. However, its cost-effectiveness for non-squamous NSCLC and the consequences of PD-L1 testing are unknown. This literature-based health economic study used CheckMate-057 trial data to model the incremental cost-effectiveness ratio (ICER) of NIV versus DOC in the Swiss healthcare … |
| Continua a leggere |
| Appuntamenti AIOM |
| XVIII Congresso Nazionale AIOM |
| Roma, 28 – 30 ottobre 2016 |
| Link all'evento |
| Quale rapporto tra beneficio e rischio nella re-biopsia nei pazienti con carcinoma polmonare EGFR mutato |
| Reggio Emilia, 20 settembre 2016 |
| Nuovi farmaci in oncologia 2016. Valore e sostenibilità |
| Ferrara, 23 settembre 2016 |
| Immunotherapy: Past, Present And Future |
| Napoli, 26 settembre 2016 |
| AIOM-AIRTUM: Presentazione Volume "I Numeri del Cancro in Italia 2016" |
| Roma, 27 settembre 2016 |
| Immuno-Oncologia: Stato Dell'arte E Update |
| Bari, 29 settembre 2016 Evento riservato ai Soci della Puglia |
| WISPO 2016 Sperimentazioni Cliniche. Il Nuovo Regolamento Europeo: dalla teoria alla pratica |
| Milano, 29 settembre 2016 |
| Combinazioni e sequenze in terapia: aspetti clinico-metodologici e farmacoeconomici |
| Roma, 29 – 30 settembre 2016 |
| Aggiornamenti nel trattamento del carcinoma polmonare non a piccole cellule con mutazione di EGFR e riarrangiamento di ALK |
| Brescia, 30 settembre 2016 |
| XVII Congresso Nazionale della Pneumologia |
| Milano, 5 – 7 ottobre 2016 |
| Micro-Ambiente Tumorale. Antiangiogenici e immunoterapia: miti e realtà |
| Milano, 11 ottobre 2016 |
| Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania |
| Benevento, 18 ottobre 2016 |
| Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania |
| Napoli, 20 ottobre 2016 |
| 4th International Conference Translational Research In Oncology |
| Meldola (FC), 8 novembre 2016 Forlì, 9 – 11 novembre 2016 |
| Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma |
| Varese, 12 novembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |